FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk

FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease Risk

A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss. Regulators in the European Union, United Kingdom, and Australia have added similar warnings, mostly for semaglutide. The FDA said the benefits of GLP-1 medications still outweigh their risks when used as directed. GLP-1 users have a new symptom to watch for: Sudden vision loss in one eye. The Food and Drug Administration (FDA) announced on November 9 that it will require drugmakers to add information to the warning labels of Ozempic, Wegovy, Mounjaro, Zepbound and other GLP-1 medications about “a potential increased risk” of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). GLP-1 medications are approved to treat type 2 diabetes and to help people lose weight and keep it off. NAION joins a growing list of side effects linked to GLP-1s, adding a second eye warning to severa

Read More

Source: Google Health